Avista Pharma Solutions Completes Expansion of Analytical Laboratories At Durham Headquarters
Expanded Service Capabilities
DURHAM, N.C., August 8, 2017 – Avista Pharma Solutions, Inc. (“Avista Pharma”) has announced that the expansion and upgrades to the Analytical Laboratories at its Durham, North Carolina facility are now complete. These enhancements will enable the company to significantly increase its capacity with a comprehensive range of capabilities for its pharmaceutical and medical device clients.
Comprised of two laboratories, the Analytical Research and Development (ARD) and Quality Control (QC) labs have now doubled in size and expanded the service offerings as the result of Avista’s capital investment. The completed Analytical Laboratories’ systems and equipment include a Thermo Scientific Orbitrap High-Resolution Mass Spectrometer, Mass-Directed Preparative Chromatography, Agilent UPLC-tandem Quad MS, Waters H-class UPLCs with six-column switching capabilities and PDA/ELSD/CAD/Single Quad MS detectors, along with upgraded Laboratory Information Management System (LIMS), Empower™ 3 Chromatography Data Software and Agilent MassHunter software with Enterprise Content Manager.
“Expanding our laboratory and adding new service offerings reinforces our commitment to providing our clients with a world-class center of excellence to assist in their product development efforts,” said Patrick Walsh, Chief Executive Officer at Avista. “Our clients choose to work with us because our skilled teams are relentless in support of their project needs.”
Using these state-of-the-art systems and equipment, Avista’s full-service offering includes:
- Chromatographic method development for assay and related substances, potential genotoxic impurities, organic volatile impurities and residual solvents
- Spectral identification using upgraded FTIR, NMR and UV-Vis instrumentation
- Structural chemistry and impurity identification through accurate mass LC-MS and generation fragmentation (MSn), 1D and 2D NMR and preparative chromatography isolation
- Fate and purge studies
- Extractable/leachable studies
- Release and stability testing
For more information about the Analytical Laboratories at all three of Avista’s facilities, please visit www.avistapharma.com.
NEW MEDIA CONTENT:
Avista Pharma on Facebook
Avista Pharma on Twitter
Avista Pharma on LinkedIn
ABOUT AVISTA PHARMA SOLUTIONS, INC.:
Avista Pharma, a portfolio company of Ampersand Capital Partners, is a contract testing, development and manufacturing organization (CDMO) encompassing more than 200,000 square feet of laboratory and manufacturing space across three locations (Agawam, Massachusetts; Durham, North Carolina and Longmont, Colorado), providing pharmaceutical, animal health and medical device clients a broad suite of scientifically-differentiated services, ranging from early stage API and Drug Product discovery, development and cGMP manufacturing, to standalone analytical and microbiology testing support. For more information about Avista Pharma Solutions, Inc., please visit us at www.avistapharma.com.
ABOUT AMPERSAND CAPITAL PARTNERS:
Ampersand is a middle market private equity firm with a focus on growth equity investments in the healthcare sector. Over the past two decades, Ampersand has managed more than $1 billion in private equity partnerships. Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Additional information about Ampersand is available at www.ampersandcapital.com.
MMI Public Relations